Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts

Journal of Cardiovascular Pharmacology

Volumn 60, Issue 2, 2012, Pages 140-149

  Noda, Kazuki ^a   Kobara, Miyuki ^a   Hamada, Junichi ^a   Yoshifuji, Yusuke ^a   Shiraishi, Tatsuya ^a   Tanaka, Takuya ^a   Wang, Jiahong ^a   Toba, Hiroe ^a   Nakata, Tetsuo ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

aldosterone; angiotensin II; heart failure; ROS production

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; GLYCOPROTEIN GP 91; MESSENGER RNA; OLMESARTAN; PROTEIN P47; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SPIRONOLACTONE; SUPEROXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL CULTURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; GENE EXPRESSION; HEART DILATATION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART WEIGHT; LIPID PEROXIDATION; LUNG WEIGHT; MALE; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HEART FAILURE; HEMODYNAMICS; IMIDAZOLES; LIPID PEROXIDATION; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCARDIAL INFARCTION; MYOCARDIUM; NADPH OXIDASE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; TETRAZOLES; VENTRICULAR FUNCTION, LEFT;

EID: 84865589272     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318258f8ce     Document Type: Article

References (41)

1. Lindpaintner K, Lu W, Neidermajer N, et al. Selective activation of cardiac angiotensinogen gene expression in post-infarction ventricular remodeling in the rat. J Mol Cell Cardiol. 1993;25:133-143.
2. Silvestre JS, Heymes C, OubénaÏssa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation. 1999;99: 2694-2701.
3. Katada J, Meguro T, Saito H, et al. Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction. Circulation. 2005;111:2157-2164.
4. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273: 1450-1456.
5. Pfeffer MA, Swedberg K, Granger CB, et al CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-766.
6. Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail. 2004;6:539-545.
7. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000;102:2700-2706.
8. Pitt B, Bakris G, Ruilope LM, et al EPHESUS Investigators. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008;118:1643-1650.
9. Zannad F, McMurray JJ, Drexler H, et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail. 2010;12:617-622.
10. Belch JJ, Bridges AB, Scott N, et al. Oxygen free radicals and congestive heart failure. Br Heart J. 1991;65:245-248.
11. Josephson RA, Silverman HS, Lakatta EG, et al. Study of the mechanisms of hydrogen peroxide and hydroxyl free radical-induced cellular injury and calcium overload in cardiac myocytes. J Biol Chem. 1991;266: 2354-2361.
12. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol. 1996;28:506-514.
13. Shiomi T, Tsutsui H, Matsusaka H, et al. Overexpression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation. 2004;109:544-549.
14. Heymes C, Bendall JK, Ratajczak P, et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol. 2003;41: 2164-2171.
15. Murdoch CE, Zhang M, Cave AC, et al. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res. 2006;71:208-215.
16. Ide T, Tsutsui H, Kinugawa S, et al. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res. 2000;86:152-157.
17. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985;312:159-163.
18. Fukui T, Yoshiyama M, Hanatani A, et al. Expression of p22-phox and gp91-phox, essential components of NADPH oxidase, increases after myocardial infarction. Biochem Biophys Res Commun. 2001;281: 1200-1206.
19. Ide T, Tsutsui H, Hayashidani S, et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res. 2001;88:529-535.
20. Li JM, Shah AM. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J Biol Chem. 2003;278:12094-12100.
21. Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
22. Qin F, Patel R, Yan C, et al. NADPH oxidase is involved in angiotensin II-induced apoptosis in H9C2 cardiac muscle cells: effects of apocynin. Free Radic Biol Med. 2006;40:236-246.
23. Keidar S, Kaplan M, Pavlotzky E, et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 2004; 109:2213-2220.
24. Miyata K, Rahman M, Shokoji T, et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol. 2005;16:2906-2912.
25. Hayashi H, Kobara M, Abe M, et al. Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis. Hypertens Res. 2008;31:363-375.
26. Kobara M, Tatsumi T, Kambayashi D, et al. Effects of ACE inhibition on myocardial apoptosis in an ischemia-reperfusion rat heart model. J Cardiovasc Pharmacol. 2003;41:880-889.
27. Kobara M, Noda K, Kitamura M, et al. Antibody against interleukin-6 receptor attenuates left ventricular remodelling after myocardial infarction in mice. Cardiovasc Res. 2010;87:424-430.
28. Bäcklund T, Palojoki E, Saraste A, et al. Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction. Cardiovasc Res. 2003;57:727-737.
29. Sydow K, Daiber A, Oelze M, et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest. 2004;113:482-489.
30. Matoba S, Tatsumi T, Keira N, et al. Cardioprotective effect of angiotensin-converting enzyme inhibition against hypoxia/reoxygenation injury in cultured rat cardiac myocytes. Circulation. 1999;99:817-822.
31. Robinson KM, Janes MS, Beckman JS. The selective detection of mitochondrial superoxide by live cell imaging. Nat Protoc. 2008;3:941-947.
32. Mukhopadhyay P, Rajesh M, Haskó G, et al. Simultaneous detection of apoptosis and mitochondrial superoxide production in live cells by flow cytometry and confocal microscopy. Nat Protoc. 2007;2:2295-2301.
33. Fraccarollo D, Galuppo P, Schmidt I, et al. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction. Cardiovasc Res. 2005;67:97-105.
34. Onozato ML, Tojo A, Kobayashi N, et al. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant. 2007;22: 1314-1322.
35. Looi YH, Grieve DJ, Siva A, et al. Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension. 2008;51:319-325.
36. Doerries C, Grote K, Hilfiker-Kleiner D, et al. Critical role of the NAD(P) H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res. 2007;100:894-903.
37. Dai DF, Johnson SC, Villarin JJ, et al. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ Res. 2011;108:837-846.
38. Wu S, Gao J, Ohlemeyer C, et al. Activation of AP-1 through reactive oxygen species by angiotensin II in rat cardiomyocytes. Free Radic Biol Med. 2005;39:1601-1610.
39. Bendall JK, Cave AC, Heymes C, et al. Pivotal role of a gp91(phox)- containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation. 2002;105:293-296.
40. Kimura S, Zhang GX, Nishiyama A, et al. Mitochondria-derived reactive oxygen species and vascular MAP kinases: comparison of angiotensin II and diazoxide. Hypertension. 2005;45:438-444.
41. Lee DS, Ghosh N, Floras JS, et al. Association of blood pressure at hospital discharge with mortality in patients diagnosed with heart failure. Circ Heart Fail. 2009;2:616-623.